Baxter submits biologics license application supplement for FEIBA NF

theflyonthewall.com

Baxter announced that the company has submitted a biologics license application supplement to the FDA for the approval of prophylaxis treatment of FEIBA NF, Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors. FEIBA NF is not indicated for prophylaxis use in the United States. Canada, The Netherlands, Israel, Australia/New Zealand, Japan and South Korea also do not have a prophylaxis indication.

Rates

View Comments (0)